Orange Book product · Brand (NDA)
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
At a glance
May 15, 2018
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 15, 2018
8 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Strength
300MG;300MG
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
NDA 022344
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
